A clinically robust mitochondrial assessment that transforms advanced cellular testing into actionable insights for optimized energy, metabolism, and personalized performance. SCOTTSDALE, Ariz., Jan. 26, 2026 /PRNewswire/ -- 10X Health System, a precision wellness company focused on data-driven human optimization, today announced the addition of 10X MitoScreen™, an advanced mitochondrial health assessment, through a strategic partnership with Verséa Discovery, Inc. leveraging their mescreenTM t

CHICAGO, Jan. 26, 2026 /PRNewswire/ -- The American Society for Clinical Pathology (ASCP), in collaboration with Pfizer and with participation from the American Society of Clinical Oncology (ASCO), announced a Request for Proposals (RFP) to support multiple Quality Improvement (QI) grant projects funded up to $250,000 per project, focused on improving biomarker testing to support frontline treatment selection in metastatic colorectal cancer (mCRC). The RFP will open January 26, 2026. ASCP will a

Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Jan. 26, 2026 /PRNewswire/ -- The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding for high-tech cures for long-term illness. A major FDA move at the beginning of the year[2] is now making it much easier to build these advanced platforms, clearing a path for companies that can treat diseases internally without the ha

Initial case conducted by Dr. David Godfrey at Glaucoma Associates of Texas The IDE study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System CAMPBELL, Calif., Jan. 26, 2026 /PRNewswire/ -- Myra Vision, a Shifamed portfolio company, today announced the first patient enrolled in its ADAPT clinical study evaluating the Calibreye™ TGT Surgical System in patients with glaucoma. This milestone represents a significant advanceme

ALACHUA, Fla., Jan. 26, 2026 /PRNewswire/ -- Amend Surgical, a medical device company focused on novel products for oral wound-care and regenerative biomaterials, today announced that it has achieved ISO 13485:2016 certification, the global standard for medical device quality management systems. Continue Reading Amend Tissue Tape The achievement of ISO 38485:2016 certification underscores Amend Surgical's commitment to safety, regulatory compliance, and operational excellence, confirming that th

ALGIERS, Algeria and AMMAN, Jordan, Jan. 26, 2026 /PRNewswire/ -- MS Pharma Group, a leading regional pharmaceutical company in the MENA region, has signed a strategic partnership agreement with Hetero Group, a global pharmaceutical company, to localize five established biosimilars across key therapeutic areas, including oncology, immunology and hematology. Continue Reading Hetero Logo (PRNewsfoto/MS Pharma) The exclusive agreement will be implemented through El Kendi – MS Pharma Group's affili

BALDWIN PARK, Calif., Jan. 26, 2026 /PRNewswire/ -- StemCyte, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared an Expanded Access (EA) program for RegeneCyte®, the company's FDA-licensed hematopoietic progenitor cell (HPC) therapy. This milestone enables eligible patients suffering from the debilitating effects of Post-Acute Sequelae of SARS-CoV-2 (Long COVID) to access the therapy while StemCyte continues its pivotal clinical research. This EA program follows

Partnership aligns risk-based patient engagement, LDCT screening, and AI-powered imaging follow-up as lung programs scale CHICAGO and NASHVILLE, Tenn., Jan. 26, 2026 /PRNewswire/ -- CancerIQ, a precision health platform supporting cancer early detection, and Azra AI, an AI-powered enterprise platform supporting imaging follow-up and care coordination, today announced a partnership designed to strengthen lung cancer screening by aligning risk-based patient identification and engagement with AI-po

SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- To enable Chinese innovative pharmaceutical companies to more efficiently connect with international resources, bioSeedin, a platform facilitating cooperation in innovative drug assets, hosted the BIOSeedin Winter Innovation Partnering Summit in San Francisco on January 11, 2026. The event centered on the "China Asset Showcase", providing an exclusive international roadshow and licensing cooperation forum dedicated to Chinese innovative drugs. Continu

Retrospective Analysis of Over 120,000 Echocardiographic Studies Provides Clinical Evidence of Diagnostic Accuracy for Heart Failure and Valvular Disease NEW YORK, Jan. 26, 2026 /PRNewswire/ -- AISAP, a leader in AI Point-of-Care Diagnostics, today announced the publication of a new clinical study in the peer-reviewed journal Frontiers in Digital Health. The research provides clinical evidence that AISAP's deep learning model can accurately detect significant valvular disease and ventricular dy